NCT03040973 - Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions

Advanced Solid Tumors Which Are cMET-dependent

Interventions

DRUG

Capmatinib

Tablet for oral use; 150 mg, 200 mg; twice a day

DRUG

Nazartinib

Capsule for oral use; 25 mg, 50 mg; once a day

DRUG

Gefitinib

tablets for oral use; 250mg; once a day

DRUG

Osimertinib

Tablets for oral use; 40 mg, 80 mg; once a day.

Trial Locations (15)

3000

Novartis Investigative Site, Leuven

20141

Novartis Investigative Site, Milan

21034

Novartis Investigative Site, Dijon

28040

Novartis Investigative Site, Madrid

30625

Novartis Investigative Site, Hanover

50937

Novartis Investigative Site, Cologne

119074

Novartis Investigative Site, Singapore

200433

Novartis Investigative Site, Shanghai

650106

Novartis Investigative Site, Kunming

02114

Massachusetts General Hospital, Boston

T6G 1Z2

Novartis Investigative Site, Edmonton

DK-2100

Novartis Investigative Site, Copenhagen

06129

Novartis Investigative Site, Perugia

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul